Recombinant Mouse GTPase KRas(Kras)

Code CSB-YP012493MO
Size Pls inquire other sizes
Source Yeast
Have Questions? Leave a Message or Start an on-line Chat
Code CSB-EP012493MO
Size Pls inquire other sizes
Source E.coli
Have Questions? Leave a Message or Start an on-line Chat
Code CSB-EP012493MO-B
Size Pls inquire other sizes
Source E.coli
Conjugate Avi-tag Biotinylated
E. coli biotin ligase (BirA) is highly specific in covalently attaching biotin to the 15 amino acid AviTag peptide. This recombinant protein was biotinylated in vivo by AviTag-BirA technology, which method is BriA catalyzes amide linkage between the biotin and the specific lysine of the AviTag.
Have Questions? Leave a Message or Start an on-line Chat
Code CSB-BP012493MO
Size Pls inquire other sizes
Source Baculovirus
Have Questions? Leave a Message or Start an on-line Chat
Code CSB-MP012493MO
Size Pls inquire other sizes
Source Mammalian cell
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Purity >85% (SDS-PAGE)
Target Names Kras
Uniprot No. P32883
Alternative Names Kras; Kras2; GTPase KRas; K-Ras 2; Ki-Ras; c-K-ras; c-Ki-ras) [Cleaved into: GTPase KRas; N-terminally processed]
Species Mus musculus (Mouse)
Expression Region 1-186
Target Protein Sequence MTEYKLVVVG AGGVGKSALT IQLIQNHFVD EYDPTIEDSY RKQVVIDGET CLLDILDTAG QEEYSAMRDQ YMRTGEGFLC VFAINNTKSF EDIHHYREQI KRVKDSEDVP MVLVGNKCDL PSRTVDTKQA QELARSYGIP FIETSAKTRQ RVEDAFYTLV REIRQYRLKK ISKEEKTPGC VKIKKC
Protein Length Full length protein
Tag Info The following tags are available.
N-terminal His-tagged
Tag-Free
The tag type will be determined during production process. If you have specified tag type, please tell us and we will develop the specified tag preferentially.
Form Lyophilized powder
Buffer before Lyophilization Tris/PBS-based buffer, 6% Trehalose, pH 8.0
Reconstitution We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20℃/-80℃. Our default final concentration of glycerol is 50%. Customers could use it as reference.
Troubleshooting
and FAQs
Protein FAQs
Storage Condition Store at -20°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
Shelf Life The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
Lead Time Delivery time may differ from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Note: All of our proteins are default shipped with normal blue ice packs, if you request to ship with dry ice, please communicate with us in advance and extra fees will be charged.
Notes Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Datasheet Please contact us to get it.

Target Data

Function Ras proteins bind GDP/GTP and possess intrinsic GTPase activity (By similarity). Plays an important role in the regulation of cell proliferation
Gene References into Functions
  1. GATAD2B interacts with C-MYC to enhance KRAS driven tumor growth. PMID: 30013058
  2. In mice that express activated KRAS in the pancreas, we found expression of GNAS(R201C) to cause development of more differentiated tumors, with gene expression pattern associated with the ductal phenotype. PMID: 30142336
  3. Study results indicate that pleural homed cancer cells harboring activating KRAS mutations are competent of malignant pleural effusion induction. This genotype-phenotype link is primarily mediated via mutant KRAS-dependent CCL2 signaling that results in the recruitment of CD11b+Gr1+ myeloid cells to the pleural space. PMID: 28508873
  4. gene expression profiles of each of the Ras isoforms in a panel of mouse tissues derived from a full developmental time course, are reported. PMID: 28117393
  5. The results show that genetic abrogation of Nrf2 impairs the malignant phenotype of K-Ras-transformed cells in vitro and in vivo, and demonstrates the critical role of Nrf2 in promoting cell survival and drug resistance in cells harboring oncogenic K-ras. PMID: 29621903
  6. These data reveal previously unknown genomic diversity among KrasG12D-initiated GEMM tumors, places them in context of human patients, and demonstrates how to exploit this inherent tumor heterogeneity to discover therapeutic vulnerabilities. PMID: 29203670
  7. Human and mouse studies reveal that different gene dosages of an activating KRAS mutation are critical determinants of pancreatic cancer biology, including early progression, metastasis, histopathology, cellular plasticity and clinical aggressiveness. PMID: 29364867
  8. transgenic mice expressing Slug and Kras in acinar cells were generated. Surprisingly, Slug attenuated Kras-induced acinar-ductal metaplasia (ADM)development, ERK1/2 phosphorylation and proliferation. Co-expression of Slug with Kras also attenuated chronic pancreatitis-induced changes in ADM development and fibrosis PMID: 27364947
  9. PTEN loss and activated Kras have synergistic effects in promoting development of intraductal papillary mucinous neoplasms and progression to pancreatic ductal adenocarcinoma. PMID: 29273451
  10. Given the significance of KRAS activity as a driver in tumorigenesis, identification of K147 acetylation as a novel post-translational modification directed by SIRT2 in vivo may provide a better understanding of the mechanistic link regarding the crosstalk between non-genetic and genetic factors in KRAS driven tumors. PMID: 27637077
  11. KY1022, a small molecule that destabilizes both beta-catenin and Ras by targeting the Wnt/beta-catenin pathway, inhibitits cellular events, including epithelial mesenchymal transformation, an initial process of metastasis, and apoptosis in colorectal cancer cells. PMID: 27835580
  12. ACSL3 is essential for mutant KRAS lung cancer tumorigenesis in vivo and is highly expressed in human lung cancer PMID: 27477280
  13. Neurofibromin regulates macrophage superoxide production via p21Ras.Neurofibromin-deficient smooth muscle cells are sensitive to oxidative stress.NADPH oxidase 2 is required for NF1 arterial stenosis.Neurofibromatosis type 1 patients have evidence of chronic oxidative stress. PMID: 27266634
  14. RAS signaling can upregulate tumor cell PD-L1 expression through a mechanism involving increases in PD-L1 mRNA stability via modulation of the AU-rich element-binding protein tristetraprolin. PMID: 29246442
  15. In a mouse lung model of KRas(G12D)-driven adenomas, co-activation of Myc drives the immediate transition to highly proliferative and invasive adenocarcinomas marked by highly inflammatory, angiogenic, and immune-suppressed stroma. PMID: 29195074
  16. Interactions between the Wnt/beta-catenin and the Kras/ERK/Foxm1 pathways are essential to restrict SOX9 expression in basal cells during pulmonary branching morphogenesis PMID: 26869074
  17. Data show that the induction of BIM in the MYC- and RAS-driven leukemia is mediated by the downregulation of miR-17-92, and suggest that induction of BIM-mediated apoptosis may be a therapeutic approach for acute lymphoblastic leukemia (ALL). PMID: 27095570
  18. Data show that cisplatin response was enhanced in human lung cancer cells when Nit1 was knocked down and mice Nit1-/-:KrasG12D/+ tumors showed increased sensitivity to cisplatin in vivo. PMID: 26967383
  19. that Kras is a major regulator of TPO and GM-CSF signaling in specific populations of hematopoietic cells. PMID: 26972179
  20. We crossed Ptf1a(Cre/+) ;Kras(G12D/+) mice with JNK1(-/-) mice to generate Ptf1a(Cre/+) ;Kras(G12D/+) ;JNK1(-/-) (Kras;JNK1(-/-) ) mice. Tumor weight was significantly lower in Kras;JNK1(-/-) mice than in Kras;JNK1(+/-) mice, whereas histopathological features were similar.we concluded that inhibition of activated JNK in pancreatic tumor stroma could be a potential therapeutic target to increase Ccl20 secretion PMID: 28837246
  21. Transgenic mouse line expressing the human Ki-Ras bearing an activating mutation (Ki-Ras((G12V))) selectively in the mammary epithelium develop estrogen receptor alpha (ERalpha)-positive ductal adenocarcinomas with 100% incidence within 3-9 months after Ki-Ras((G12V)) induction. PMID: 28745321
  22. It has been concluded that VMP1-mediated autophagy cooperated with Kras to promote pancreatic ductal adenocarcinoma initiation. PMID: 27415425
  23. High KRAS expression is associated with Gastric Tumorigenesis. PMID: 28760854
  24. Study underscores genomic alterations that represent early events in the development of Kras mutant LUAD following Gprc5a loss and tobacco carcinogen exposure. PMID: 28653505
  25. a KrasG12D mouse model that reproducibly develops JMML-like disease. This model will prove useful for preclinical drug studies and for elucidating the developmental origins of pediatric neoplasms. PMID: 28846072
  26. In the absence of TP53, chronic imflammaiton leads to the development of several rare K-ras-independent forms of PC, with infrequent PDAC. PMID: 27991926
  27. KrasG12D-driven proliferation of pancreatic ductal epithelial cells (PDECs) depends on an EGFR signaling loop engaging the oncogenic transcription factor c-MYC. PMID: 26592448
  28. median survival of KPIC mice was longer than that of LSL-KrasG12D; Ink4flox/flox; Ptf1/p48-Cre mice (KIC) (89 vs 62 days) and shorter than that of KRAS (KrasG12D), TP53 (Trp53R172H/+) and Ptf1/p48-Cre (KPC) mice PMID: 28475592
  29. Loss of N-cadherin in the context of oncogenic K-ras leads to increased pancreatic intraepithelial neoplasia (PanIN) incidence and progression. PMID: 26477318
  30. activating mutations in GNAS and Kras cooperatively promote murine pancreatic tumorigenesis PMID: 26257060
  31. the Kras(mut) allele was heterogenous in primary tumors yet homogenous in metastases, a pattern consistent with activated Kras(mut) signaling being a driver of progression to metastasis. PMID: 28289141
  32. Using an extensive collection of novel murine cell lines we have identified distinct roles for Kras and Pten on MUC1 and EMT in vivo and in vitro. The data has implications for future design of combination therapies targeting Kras mutations, Pten deletions and MUC1 vaccines. PMID: 26973247
  33. a potent tumor-suppressive function for Lfng PMID: 26279302
  34. pancreatic ductal cells, whereas exhibiting relative resistance to oncogenic Kras alone, can serve as an effective cell of origin for pancreatic ductal adenocarcinoma in the setting of gain-of-function mutations in p53 PMID: 26592447
  35. In vivo treatment of the KRAS(G12D)-induced Langerhans cell histiocytosis -like mouse with the cholesterol-lowering drug atorvastatin ameliorated the pathology, implicating statins as potential therapeutics against a subset of pulmonary Langerhans cell histiocytosis. PMID: 28550040
  36. overactivation of Kras signaling in type II collagen-positive, immature osteoprogenitor cells, but not in mature osteoblasts, substantially increases the number of their descendant stromal cells and mature osteoblasts, and subsequently increases bone mass. PMID: 27735946
  37. demonstrate the tumor suppressor function of WT Kras in oncogenic Kras-induced leukemogenesis and elucidate its underlying cellular and signaling mechanisms. PMID: 27055865
  38. Modification of the tumor microenvironment in KRAS or c-MYC-induced ovarian cancer-associated peritonitis has been described. PMID: 27483433
  39. we provide genetic evidence that the wild-type H-Ras and K-Ras proteins are bioequivalent in spite of their different structural and biological properties PMID: 27872088
  40. KRAS K104Q mutant exhibited defects in both guanine nucleotide exchange factors -mediated exchange and GTPase-activating proteins -mediated GTP hydrolysis, consistent with NMR-detected structural perturbations in localized regions of KRAS important for recognition of these regulatory proteins. PMID: 28154176
  41. farnesylation of K-Ras was required for its packaging within extracellular nanovesicles, yet expressing a K-Ras farnesylation mutant did not decrease the number of nanovesicles or the amount of Alix protein released per cell. PMID: 27909058
  42. The K-Ras(V14I) activating protein is able to induce cancer, although at a much lower level than the classical K-Ras(G12V) oncogene, and that it can be significantly modulated by both genetic and non-genetic events. PMID: 27174785
  43. Gli1 and Gli2 exhibited different functions in the regulation of p63 expression or proliferation of p63(+) cells in Kras-AR driven tumors. PMID: 27760825
  44. our data suggest that GGPPS is essential for maintaining fetal lung branching morphogenesis, which is possibly through regulating K-Ras prenylation. PMID: 27106761
  45. We establishment the transgenic mouse model of K-ras(G12D) p53(loxP/loxP) and found that K-ras mutation and p53 deletion within the ovarian surface epithelium gave rise to ovarian lesions with a hyperproliferation and endometrioid glandular morphology PMID: 28032649
  46. the expression of EGFRL858R in KrasG12V-driven lung adenocarcinoma limits tumor progression due to the induction of a transient oncogenic conflict PMID: 27775074
  47. K-Ras knockout (KO) mouse embryonic fibroblasts (K-ras(-/-) ) stimulated with transforming growth factor-beta1 (TGF-beta1) exhibited reduced proliferation and impaired mobility than wild-type fibroblasts PMID: 26873620
  48. findings demonstrate that advanced gastric tumorigenesis requires oncogenic KRAS or BRAF in concert with aberrant STAT3 activation in epithelial precursor cells of the glandular stomach PMID: 26837764
  49. oncogenic KRas-induced increase in fluid-phase endocytosis has a key role during cellular transdifferentiation in pancreatic acinar cells. This result supports emerging evidence for endocytosis playing a crucial role in regulating the signaling output of the cells PMID: 28057438
  50. This study reveals KRAS(G12D) uniquely regulates tumor cells via heterotypic stromal cells. By exploiting heterocellularity, reciprocal signaling enables KRAS(G12D) to engage oncogenic signaling pathways beyond those regulated in a cell-autonomous manner. PMID: 27087446
  51. We also uncovered that Prox1-heterozygosis markedly increases the formation of acinar-to-ductal-metaplasias and early neoplasias, and enhances features associated with inflammation, in mouse pancreatic tissues expressing oncogenic Kras. PMID: 26992918
  52. The mutant KRas can initiate the transcription of the epidermal growth factor receptors and its ligands by increasing mitochondrial generation of ROS and activation of NF-kB signaling through protein kinase D1. PMID: 26947075
  53. Findings suggest that COX-2 deletion contributes to the repression of K-ras-induced lung tumorigenesis by reducing tumor cell proliferation, decreasing the production of PGE2, and increasing the production of 13,14-dihydro-15-keto-PGE2, possibly via the MAPK pathway. PMID: 26452035
  54. Data indicate that KrasG12D;Pdx1-Cre mouse model enables one to monitor the progression of pancreatic cancer (PC) from the onset of precursor lesions to cancer development. PMID: 26516699
  55. in this overview are the features of various KRAS-driven genetically engineered mouse models (GEMMs) of non-small cell lung cancer--{REVIEW} PMID: 26331885
  56. Binase-KRAS interaction interferes with the function of GEFs and stabilizes the inactive GDP-bound conformation of RAS thereby inhibiting MAPK/ERK signaling and oncogenic activity. PMID: 27066977
  57. Data show that in both GTP- and GDP-bound states of the K-Ras, the catalytic domain exhibited similar membrane orientations. PMID: 26718888
  58. our results highlight the importance of Pas1 as a tumor-modifier locus, attribute to it a novel role as a major regulator of transcription in lung tumor nodules and strengthen the candidacy of the Kras gene as the effector of this locus. PMID: 26966001
  59. demonstrated that despite having both Kras and Pik3ca mutations at the time of tumor initiation from loss of APC PMID: 26276752
  60. coexpression of BRAF(V600E) and KRAS(G12D) in early tumorigenesis leads to negative selection due to oncogene-induced senescence PMID: 26028035
  61. CDK1 is a synthetic lethal target for KRAS mutant tumors. PMID: 26881434
  62. Kras is the unique Ras family member that plays a critical role in early B cell development and late B cell maturation PMID: 26773157
  63. CREB plays a key role in the K-RAS(V12)-mediated neoplastic phenotype and represents a suitable therapeutic target for murine and human K-RAS(V12)-induced tumors PMID: 25934695
  64. Modulation of Polycomb repressive complexes by either Ezh2 overexpression or Eed deletion enhances KRAS-driven adenomagenesis and inflammation PMID: 26766588
  65. Long-term ERK inhibition in KRAS-mutant pancreatic cancer is associated with MYC degradation PMID: 26725216
  66. results suggest that XPC may help repair DNA damage caused by KRAS-mediated production of ROS. PMID: 26554912
  67. Data suggest that over-expression of lincRNA-p21 promotes up-regulation of p21 at both mRNA and protein levels in hepatic stellate cells; expression of lincRNA-p21 and p21 is down-regulated in cirrhotic liver patients as compared to normal subjects. PMID: 26433205
  68. These results demonstrate that mutant K-Ras can influence intestinal homeostasis on multiple levels. PMID: 26079371
  69. The data suggest a role for redox-dependent activation of wild-type KRAS through cysteine 118 in oncogenic HRAS-driven tumorigenesis. PMID: 25902334
  70. KRAS plays an important role in regulating the embryo implantation process. PMID: 25999213
  71. mutant Kras lung tumours are not a single disease but rather a heterogeneous group comprising two classes of tumours with distinct metabolic profiles, prognosis and therapeutic susceptibility, depending on their relative mutant allelic content PMID: 26909577
  72. EphA2 acts as a KRas cooperative tumor suppressor PMID: 26542681
  73. Simultaneous activation of K-RAS and beta-catenin in embryonic renal epithelium leads to neoplasms similar to human Wilms tumor and associated with activation of TP53 and up-regulation of E2F1. PMID: 25934441
  74. decreased lung tumorigenesis with point mutation at C118 PMID: 25394415
  75. The Akt1(Myr)/KRas(G12D) model holds promise for delineating the tumor biology and biomarkers critical for understanding their cooperation in cancer oncogenesis and future targeting in therapeutic strategies. PMID: 25748236
  76. Our results suggest that DNMT3A mutations and oncogenic RAS cooperate to regulate hematopoietic stem and progenitor cells and promote myeloid malignancies. PMID: 25801914
  77. Ras induction of ZEB1 is required for tumour initiation in a lung adenocarcinoma model via Pten repression. A lower threshold of ZEB1 is sufficient for cancer initiation, whereas further induction is necessary for tumour metastasis. PMID: 25434817
  78. Data suggest that accumulation of proto-oncogene protein Kras mutation occurs later with chronic vanadium pentoxide (VP) exposure and is likely not an early event in VP-induced lung carcinogenesis. PMID: 26232258
  79. Anatomical site-specific Cre-loxP recombination throughout the genital tract of MUC1KrasPten mice leads to MUC1 positive genital tract tumors, and the development of these tumors is influenced by the anatomical environment PMID: 25078979
  80. Data show that K-ras mutation (K-rasLA1) mice, vascular endothelial growth factor (VEGF) is expressed in papillary tumor cell subtypes from large adenocarcinomas. PMID: 25484066
  81. skin-targeted deletion, Sag significantly accelerated Kras(G12D)-induced papillomagenesis. PMID: 26056141
  82. loss of the wild-type KRAS allele is a secondary mutation in all T-ALL cells; wild-type KRAS acts as a tumor suppressor in the T-cell lineage in mice PMID: 25371176
  83. overexpression of Snail in PDAC cells increased SCF levels, and the media conditioned by Snail-expressing PDAC cells promoted mast cell migration. PMID: 24944064
  84. c-Met targeting enhances the effect of irradiation and chemical agents against malignant colon cells harboring a KRAS mutation. PMID: 25427200
  85. Neuronal NF1/RAS regulation of cyclic AMP requires atypical PKC zeta activation, which is perturbed in neurofibromatosis type 1. PMID: 25070947
  86. Our findings indicated that synergistic signaling of KRAS(G12D) and TRbetaPV led to increased MYC expression. PMID: 25246276
  87. Binding of RAGE to oncogenic KRAS facilitates hypoxia-inducible factor 1 (HIF1)alpha activation and promotes pancreatic tumor growth under hypoxic conditions. PMID: 25341034
  88. Nupr1 aids oncogenic Kras to bypass senescence in a manner that cooperatively promotes pancreas intraepithelial neoplasia formation. PMID: 24902898
  89. kappaB-Ras deficiency consequently leads to significantly increased tumor growth that can be dampened by inhibiting either Ral or NF-kappaB pathways, revealing the unique tumor-suppressive potential of kappaB-Ras proteins. PMID: 25220458
  90. Rare codon bias of KRAS plays an integral role in tumorigenesis. PMID: 25437878
  91. Data show that proteinase-activated receptor (PAR)-2-dependent inflammatory signaling as an essential component of matriptase-mediated and potentiation of ras-mediated oncogenesis. PMID: 24469043
  92. this is the first study characterizing the in vivo functions of Notch1 and Notch2 in Kras(G12D)-driven NSCLC tumorigenesis PMID: 24509876
  93. Genetic deficiency of CD98hc protects against Ras-driven skin carcinogenesis. PMID: 25267066
  94. IER3 supports KRASG12D-associated oncogenesis in the pancreas by sustaining ERK1/2 phosphorylation via phosphatase PP2A inhibition. PMID: 25250570
  95. KRAS signaling, via p110alpha to activate RAC1, is required for transformation in Kras(G12D/+);Ptf1a(Cre/+) mice. PMID: 25311989
  96. Data indicate that forkhead box M1 protein (FOXM1) is required for K-Ras-mediated lung tumorigenesis. PMID: 24213573
  97. In KRAS-mutant mice, nicotine promotes pancreatic carcinogenesis and tumor development via down-regulation of Gata6 to induce acinar cell dedifferentiation. PMID: 25127677
  98. We show that loss of Scrib and activated oncogenic KRas cooperate in vivo, resulting in more aggressive lung tumors PMID: 24276238
  99. Inflammation-induced NFATc1-STAT3 transcription complex promotes pancreatic cancer initiation by KrasG12D PMID: 24694735
  100. Trim62 loss cooperates with K-Ras mutation in tumourigenesis and metastasis in vivo, indicating that decreased levels of TRIM62 may play an important role in the evolution of lung cancer. PMID: 24890125

Show More

Hide All

Subcellular Location Cell membrane, Lipid-anchor, Cytoplasmic side, Cytoplasm
Protein Families Small GTPase superfamily, Ras family
Database Links

KEGG: mmu:16653

STRING: 10090.ENSMUSP00000032399

UniGene: Mm.383182

Most popular with customers

  Tel: 301-363-4651
  Email: support@cusabio.com
  Distributors Worldwide

Newsletters

Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

Copyright © 2007-2018 www.cusabio.com CUSABIO TECHNOLOGY LLC All Rights Reserved. 鄂ICP备15011166号-1